ResMed (RMD) agreed to sell its MatrixCare business to Frazier Healthcare Partners in an all-cash transaction valued at $490 million, subject to customary closing conditions. The deal supports capital redeployment for ResMed and is generally viewed positively as it streamlines the company’s health-tech portfolio ahead of closing.
ResMed (RMD) agreed to sell its MatrixCare business to Frazier Healthcare Partners in an all-cash transaction valued at $490 million, subject to customary closing conditions. The deal supports capital redeployment for ResMed and is generally viewed positively as it streamlines the company’s health-tech portfolio ahead of closing.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
